Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Magn Reson Med. 2012 Jun 12;69(5):1443–1450. doi: 10.1002/mrm.24355

Figure 4.

Figure 4

3-BP enters cells via MCT1 in SCC tumor. (a) In vitro clonogenic cell survival assay in the presence of MCT1 inhibitor CHC. (b) 13C MR spectroscopy of metabolites after intravenous injection of hyperpolarized 13C-labeled pyruvate in a SCC tumor. (c) Metabolic 13C MRI of hyperpolarized 13C-labeled pyruvate in SCC tumors with or without pretreatment of CHC obtained 30 s after 13C-pyruvate injection. (d) Pretreatment of MCT1 inhibitor CHC significantly suppressed lactate/total 13C and lactate/pyruvate ratios calculated from whole tumor regions in 13C MRI images.